title: Mesenchymal stem cells are injured by complement after their contact with serum.
abstract: Despite the potent immunosuppressive activity that mesenchymal stem cells (MSCs) display in vitro, recent clinical trial results are disappointing, suggesting that MSC viability and/or function are greatly reduced after infusion. In this report, we demonstrated that human MSCs activated complement of the innate immunity after their contact with serum. Although all 3 known intrinsic cell-surface complement regulators were present on MSCs, activated complement overwhelmed the protection of these regulators and resulted in MSCs cytotoxicity and dysfunction. In addition, autologous MSCs suffered less cellular injury than allogeneic MSCs after contacting serum. All 3 complement activation pathways were involved in generating the membrane attack complex to directly injure MSCs. Supplementing an exogenous complement inhibitor, or up-regulating MSC expression levels of CD55, one of the cell-surface complement regulators, helped to reduce the serum-induced MSC cytotoxicity. Finally, adoptively transferred MSCs in complement deficient mice or complement-depleted mice showed reduced cellular injury in vivo compared with those in wild type mice. These results indicate that complement is integrally involved in recognizing and injuring MSCs after their infusion, suggesting that autologous MSCs may have ad-vantages over allogeneic MSCs, and that inhibiting complement activation could be a novel strategy to improve existing MSC-based therapies.
authors.affiliation: Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Feng
authors.initials: F
authors.lastname: Lin
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D018958:CD55 Antigens / Q000235:genetics / Q000276:immunology; D003167:Complement Activation / Q000187:drug effects* / Q000276:immunology; D051056:Complement Inactivating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003165:Complement System Proteins / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007074:Immunoglobulin G / Q000494:pharmacology* / Q000627:therapeutic use; D056747:Immunomodulation; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000276:immunology* / Q000473:pathology; D051379:Mice; D061251:Primary Cell Culture; D044967:Serum; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D015854:Up-Regulation
chemical_list: D018958:CD55 Antigens; D051056:Complement Inactivating Agents; D007074:Immunoglobulin G; D003165:Complement System Proteins